Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.02%
1,101.59
+0.22
+0.02%
—1,101.371,103.631,103.631,091.41——
SIXC
Communications
SIXC
Communications
SIXC
-1.88%
601.81
-11.54
-1.88%
—613.35613.35613.35601.49——
SIXE
Energy
SIXE
Energy
SIXE
-0.59%
1,191.79
-7.04
-0.59%
—1,198.831,199.681,199.751,187.98——
SIXI
Industrials
SIXI
Industrials
SIXI
-1.02%
1,738.04
-17.91
-1.02%
—1,755.951,754.061,756.031,734.69——
SIXM
Financials
SIXM
Financials
SIXM
-0.64%
634.43
-4.08
-0.64%
—638.51637.41637.41633.05——
SIXR
Staples
SIXR
Staples
SIXR
-0.20%
841.81
-1.71
-0.20%
—843.52843.35846.40840.16——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.16%
216.30
+0.32
+0.16%
—215.95215.95216.73215.25——
SIXT
Technology
SIXT
Technology
SIXT
+2.48%
3,216.77
+77.86
+2.48%
—3,138.913,189.303,217.623,174.76——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.31%
937.23
+2.86
+0.31%
—934.37934.72937.29927.50——
SIXV
Health care
SIXV
Health care
SIXV
-1.67%
1,452.80
-24.63
-1.67%
—1,477.431,474.121,474.121,452.13——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.45%
2,390.99
+10.80
+0.45%
—2,380.192,389.342,396.912,380.47——
LCTX:TLV
Lineage Cell Therapeutics Inc
ILA 491.50
0.00%
(0.00) 1D
Apr 24, 1:44:41 PM GMT+3  ·   ILA
All symbols
SymbolPriceChange% Change
Generating top insights for LCTX...
Open
ILA 491.50
High
ILA 491.50
Low
ILA 491.50
Mkt. cap
384.84M
Avg. vol.
5.21K
Volume
7.00
52-wk high
ILA 666.00
52-wk low
ILA 140.10
Shares outstanding
249.09M
No. of employees
75
News stories
From sources across the web
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc
CEO-
Employees75
Founded1990
Headquarters-
SectorBiotechnology
Websitelineagecell.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
1.50M
2.76M
3.68M
6.61M
Cost of goods sold
2.98M
3.14M
184.00K
17.26M
Cost of revenue
2.98M
3.14M
184.00K
17.26M
Research and development expenses
169.00K
-
3.09M
-8.96M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.86M
4.56M
4.19M
4.85M
Operating expense
5.03M
4.56M
7.28M
-4.11M
Total operating expenses
8.01M
7.70M
7.47M
13.16M
Operating income
-6.50M
-4.94M
-3.79M
-6.55M
Other non operating income
2.12M
-12.71M
-26.56M
1.29M
EBT including unusual items
-4.14M
-30.36M
-29.75M
-4.39M
EBT excluding unusual items
-4.14M
-15.52M
-29.76M
-4.38M
Income tax expense
-
-
-
-5.28M
Effective tax rate
-
-
-
120.33%
Other operating expenses
-
-
-
-
Net income
-4.14M
-30.46M
-29.78M
851.00K
Net profit margin
-275.57%
-1,101.77%
-809.05%
12.88%
Earnings per share
-0.02
-0.13
-0.13
-
Interest and investment income
478.00K
454.00K
366.00K
393.00K
Interest expense
-
-
-
-
Net interest expenses
478.00K
454.00K
366.00K
393.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-6.34M
-4.77M
-3.61M
-6.36M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer